Open AccessBiosimilars in India; current status and future perspectives
Author(s) -
Bikash Ranjan Meher,
Sakthi Balan,
Rashmi Ranjan Mohanty,
Monalisa Jena,
Smita Das
Publication year - 2019
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 36
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/jpbs.jpbs_167_18
Subject(s) - biosimilar , biopharmaceutical , guideline , medicine , business , marketing , microbiology and biotechnology , pathology , biology
Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in early 2000. India is one of the leading manufacturers of similar biologics. India has developed a new guideline in 2012 for the pre- and post-marketing approval of similar biologics.